Originally, Illumina performed 73 CEU samples, 77 YRI samples, and 75 CHB+JPT samples on Human 610-Quad arrays. Since one of our criteria for results evaluation is the overlap of the CNVs between offspring and parents, we only use the CEU and YRI samples that are form complete parents-child trios, which correspond to 14 CEU trios and 20 YRI trios. Two CEU trios and three YRI trios are excluded for further analysis due to high noise of the data or chromosome-wide copy number aberrations, which are not expected in normal tissue. CHB+JPT samples are independent individuals and we do not observe serious low-quality arrays, so all the 75 CHB+JPT samples are used in our study. For xCNA when genotype in normal tissue is available, the emission probability of BAF is as follows. If the genotype in normal tissue is homozygous,
, and p e is the genotyping error (assume it is a known constant), and q e = 1 − p e . If the genotype in normal tissue is heterozygous and under the assumption of tissue contamination, for state z = 1, 7,
If it is assumed that there is no tissue contamination, all the above equations hold except that for states z = 2, 4, 6, 8
B.2 Notations
Let L be the number of SNP probes, and let N be the number of distinct states in the HMM. The input data, denoted as X ={pos, LRR, BAF, λ, G}, includes the probe positions (pos), the logR ratio (LRR, denoted by
, parameters of state duration λ = {λ j , 1 ≤ j ≤ N }, and an optional input G = {g i , 1 ≤ i ≤ L}, the genotypes of all the SNPs in normal tissue. The parameters of the HMM are Θ = {π r,z , µ r , σ r , π b,z , µ b , σ b , A}. Specifically, {π r,z , µ r , σ r } are the parameters for the emission probability of LRR, where π r,z are the mixture proportions of the uniform components, µ r and σ r indicate all the mean, standard deviation parameters of LRR. Similarly, {π b,z , µ b , σ b } are the parameters for the emission probability of BAF.
} is the transition probability matrix. We need to define some additional notations:
• q i : the state at position i,
• κ z : the probability that state of the first SNP probe is state z,
• e(i, z): the emission probability of state z at position i,
• α i (j, k): the transition probability from state j to k,
Most of the computations are carried out in log scale to avoid underflow or overflow. A utility function logsumexp is used to facilitate the computation. Specifically, it is defined as logsumexp j (v) = log j exp(v j ) , where v = {v j } is a vector.
B.3 Viterbi Algorithm
Given all the parameters, find the best path. Input X, Θ Output path: the most likely path; logPv: the log probability of the most likely path; Intermediate Variables v(i, z): p(the most likely path ending at position i | q i = z); path.m(i − 1, z): the most likely state at position i − 1, given q i = z. Algorithm
where max j (v) returns the maximum value and argmax j (v) returns the index of the maximum value.
3. Termination
path(i) = path.m(i, path(i + 1)) (B-8)
B.4 Forward Algorithm
Given all the parameters, find the forward probabilities. Input X, Θ Output f (i, z): forward probability, p(x 1 , x 2 , ..., x i , q i = z|Θ); overall likelihood log(p(X|Θ)). Algorithm 1. Initialization:
Recursion, for i ∈ (L : 2) and for z ∈ (1 : N ),
B.6 Posterior Probability
Calculate the posterior probability based on forward and backward algorithm. Input Forward probability f L×N = {f (i, z)}, backward probability b L×N = {b(i, z)}, and overall likelihood logP = log(p(X|Θ)). Output γ(i, z): posterior probability p(q i = z|X, Θ). Algorithm
B.7 Baum-Welch Algorithm
Here we only describe one-step update of the Baum-Welch Algorithm. The whole algorithm is simply repeats of this one-step update, plus the initial values of the parameters and a convergence criterion. Input X and Θ 0 . Here Θ 0 is either the initial values of the parameters or the parameter estimates from previous iteration.
Output
Estimated parameters Θ 1 ; logP: the log likelihood from each iteration.
Algorithm
(1) Estimate the posterior probabilities that one SNP belongs to one HMM state.
The initial probability κ z is simply the posterior probability of being state z at position 1, therefore the new estimate of κ z , denoted as κ z , is
(2) Estimate the transition probability a jk . Denote the estimated a jk as a jk , for j = k
(B-28) (3) Estimate {π r,z , µ r,z , σ r,z }, the parameters for the emission probability of LRR. Because the likelihoods for LRR and BAF are independent with each other given the states, we estimate {π r,z , µ r,z , σ r,z } by maximizing the mixture density p(r|z) = π r,z /R m + (1 − π r,z )φ(r; µ r,z , σ r,z ). For each observation r i , we calculate the probability it belongs to the uniform component (U r,z ) and the normal component (N r,z ) respectively:
where ξ i indicates the mixture component (of LRR) of probe i. Therefore the new estimates for π r,z , µ r,z , and σ r,z are respectively
.
(B-33)
For those states that share the same number of copies, the parameters µ r,z and σ r,z can be estimated by combining those states. For example, state 1 and 2 both have copy number 2, thus
(B-35)
(4) Estimate {π b,z , µ b,z,h , σ b,z,h }, the parameters for the emission probability of BAF. The distribution of BAF is a mixture of a uniform distribution and H z normal distributions, where H z varies from 1 to 5, depending on the state z. The estimation of µ b,z,h and σ b,z,h is the most complicate part of our algorithm, mainly because of the truncation of BAF values at 0 and 1. Parameter estimation for truncated normal distribution is more computationally demanding and less stable than non-truncated normal distribution. Therefore we try to avoid the truncated normal distribution as long as it is possible. First, state 3 is a special case because it is the null state with both alleles deleted. The likelihood of state 3 is composed of a uniform component and a normal component. As mentioned in the main text, we assume the mean value of its normal component is 0.5. We further assume the standard deviation is smaller than 0.15 so that the probability of truncation is smaller than 0.001, therefore as an approximation, we can estimate the standard deviation as if it is non-truncated normal distribution. The possible bias brought by the relatively small standard deviation can be compensated by employing a bigger weight for the uniform component. Furthermore, this null state have significantly lower LRR, so that limited degree of bias in its BAF emission probability will not bring big changes of the final posterior probability estimates.
Next, we consider all the other states except state 3. For the normal distributions corresponding to homozygous genotypes, since µ b,z,1 = 0.0 and µ b,z,Hz = 1.0 are fixed, we only need to estimate the standard derivations, which is straightforward because the truncation point is exactly the the mean values. Specifically, we can simply use the observed b i s such that 0 < b i < 1 to estimate the standard deviations. For all the other normal components (which correspond to heterozygous genotypes), except for the tissue contamination mixtures such as (A, AB), it is safe to assume the mean values are far away from the boundary (0 or 1) so that the truncation effect can be neglected. For example, based on the parameters used in PennCNV [1] , the minimum distance between a mean value of any heterozygous genotype class and the boundary is bigger than five standard deviations. In our method, we allow the data to estimate the parameters. But we add the restriction that for all the normal components corresponding to heterozygous genotypes, except for the tissue contamination mixtures, the minimum distance between the mean value and the boundaries (0 or 1) is 3.3 standard deviations, so that the probability of truncation is smaller than 0.001. Therefore, as an approximation, we can also estimate these normal components using only those b i s such that 0 < b i < 1.
Finally, for the two tissue contamination mixtures, the truncated normal distributions are inevitable. We will use all the observed b i s, including those that are exactly 0 or 1 to estimate the corresponding parameters. Now we discuss more specifically the estimation algorithm. For each observation of BAF, denoted as b i , we first calculate the probability it belongs to the uniform distribution of state z, (denoted as U b,z ) and one of the normal distribution of state z 
If 0 < b i < 1, for all the genotype classes
where η i indicates the mixture component (of BAF) of probe i, and the weights w z,h have been described in main text.
With the above posterior probability estimates, let Ω = {i; 0 < b i < 1}, the new estimate for π b,z is
. (B-42)
Next, we seek to update the estimation of µ b and σ b . For all the states where the mean parameters are not fixed, except the tissue contamination mixtures, the mean parameter can be estimated by
Then given the estimated mean value or the fixed mean value, which are both denoted as µ b,z,h to simplify the notation, the variance can be estimated by
If one genotype class is consistent with more than one HMM states, the corresponding parameters should be estimated by combining the data. For example, both state 1 and 2 have genotype AA and BB. The corresponding parameters should be estimated by merging the data (µ b,z,h is already set as 0 or 1):
The parameters of the tissue contamination mixtures are estimated under the assumption of truncation at 0 or 1, respectively. Note we assume the distribution is only truncated at one side because the probability of truncation at the other side is extremely small. We first briefly introduce the parameter estimations of truncated normal in regular situations with i.i.d. observations and then describe a modified version for our HMM.
Following Halperin [2] , suppose (x 1 , x 2 , ..., x n ) are n independent samples from N (µ, σ 2 ) distribution and the value of the s samples (x 1 , x 2 , ..., x s ) that are smaller than T are observed while for the remaining n − s samples, we only know they are no less than T , but do not know their values. Thus the sample likelihood is given by
Let h = (T − µ)/σ and let x be the sample mean of (x 1 , x 2 , ..., x s ),
Then the MLE can be obtained by solving the following two equations:
where
Equation (B-49) and (B-50) can be further written as
and
After some further simplification,
where p = s/n is the proportion of un-truncated data. Solution of Equation (B-57),ĥ can be found by numerical method. Then µ can be estimated by T −ĥσ, and σ can be estimated by Equation (B-54) by plugging inĥ.
If the samples are left-truncated. The above procedure can still be used. After we obtainĥ, just flip its sign to get MLE of h. The standard deviation can be estimated by
All the above discussion are based on observations (x 1 , x 2 , ..., x n ) that are definitely generated from a truncated normal distribution. However, in the EM algorithm of HMM, we do not have a group of b i s that are exactly from the truncated normal distribution. Instead, we have the posterior probability that each b i is from the truncated normal distribution. This problem can be circumvented as follows. In order to estimate the mean and the standard deviation, the sufficient statistics needed are simply the first/second moments of the un-truncated data (x 2 and x in equation (B-55)) and the proportion of un-truncated data (p), which can all be estimated easily by b i s and the related posterior probabilities. For example, in order to estimate the parameters for the mixture (A, AB), we first estimate γ(i, 4, N b,4,2 ), the posterior probability that b i arises from the mixture (A, AB). Then let Ω = {i; 0 < b i < 1} and Ω 0 = {i;
, (B-59)
(B-61)
Now given the sample moments of the un-truncated data (b and b 2 ), and estimation of the proportion of un-truncated data (p), we can use the above approach to estimate the mean and variance of the genotype class (A, AB).
C Empirical measurements of tumor purity
Let β O and β T be the observed mean value of BAF and expected BAF in pure tumor tissue. Given the assumption that BAF can be approximated by the ratio of the number of B alleles and the total number of alleles, we have
where n A and n B are the number of A or B alleles in pure tumor tissue, respectively. Therefore p T can be estimated as
Let β O,G be the observed mean BAF value for genotype or genotype mixture G. When copy number is 1, we update β O,(A,AB) and β O,(B,AB) by taking into account of systematic dye bias as follows: Then we can separately plug in β O,1 , β O,2 and β O,3 into equation (C-3), together with the corresponding n A and n B , to estimate p T . We denote the estimates of p T from β O,1 , β O,2 , and β O,3 as p T 1 , p T 2 , and p T 3 , respectively. As shown in Figure 5 (a) in the main text, p T 1 and p T 2 are highly consistent. Overall, p T 1 and p T 3 are also consistent ( Figure C-1) . However p T 1 and p T 3 have larger discrepancy than p T 1 and p T 2 . This may be due to the dye bias, which has been completely corrected by equation C-4 and C-5.
The clinically estimated tumor purity tends to be very high despite the apparent pattern in the data which indicates a relatively low tumor purity. An example that the extra band in the BAF plot (when copy number is one) indicates a relatively low tumor purity (71% from our data-driven estimates), while the clinically estimated tumor purity is 100%. 
